Ultrasound contrast firm Sonus Pharmaceuticals of Bothell, WA, is looking for a new marketing partner in Asia after its licensing deal with Daiichi Pharmaceutical of Japan collapsed. Daiichi and Sonus signed an agreement in 1994, which gave Daiichi
Ultrasound contrast firm Sonus Pharmaceuticals of Bothell, WA, is looking for a new marketing partner in Asia after its licensing deal with Daiichi Pharmaceutical of Japan collapsed. Daiichi and Sonus signed an agreement in 1994, which gave Daiichi rights to Sonus' EchoGen agent in Japan and nine Pacific Rim countries. Daiichi had paid Sonus $12.8 million in option, licensing, and milestone fees as of September 1998.
Daiichi completed phase 1 clinical trials for EchoGen in December 1997 but failed to begin phase 2 studies after that, according to Sonus. Sonus is in the process of looking for a new Asian marketing partner, for both EchoGen and SonoGen (QW7437), the company's next ultrasound contrast agent.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.